Clinical Trial Update: An Efficacy and Safety Study of Ravulizumab in Adult Participants With NMOSD [Phase 3]

View source ↗

Summary

Phase 3 trial of ravulizumab in adults with neuromyelitis optica spectrum disorder has completed, with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Neuromyelitis Optica
• Neuromyelitis Optica Spectrum Disorder

Drugs mentioned

• Ravulizumab (ravulizumab)

Snippet

Sponsor: Alexion Pharmaceuticals, Inc. | Conditions: Neuromyelitis Optica, Neuromyelitis Optica Spectrum Disorder | Phase 3 | Status: COMPLETED | Results posted: 2023-08-09